Haisco Pharmaceutical Group Co., Ltd.

002653

CNE100001BC7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2025-12-04			5-day change	1st Jan Change
60.42 ^CNY	+1.55%		+4.84%	+81.71%

Nov. 03	Haisco Pharma Gets Nod for Myasthenia Gravis Drug Trial	MT
Oct. 29	Haisco Pharmaceutical's Q3 Profit Down 23%, Revenue Up 22%	MT

Haisco Pharma Gets Nod for Myasthenia Gravis Drug Trial

Published on 11/03/2025 at 11:03 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Haisco Pharmaceutical Group Co., Ltd.

Nov. 03	Haisco Pharma Gets Nod for Myasthenia Gravis Drug Trial	MT
Oct. 29	Haisco Pharmaceutical's Q3 Profit Down 23%, Revenue Up 22%	MT
Oct. 28	Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
Oct. 14	Haisco Pharmaceutical's Kidney Drug Gains Breakthrough Therapy Designation in China	MT
Oct. 09	Haisco Pharmaceutical Gets Acceptance for Investigational New Drug Application for Muscular Dystrophy Indication	MT
Sep. 22	Haisco Pharmaceutical Gets Regulatory Greenlight for Pediatric Use of Anesthetic; Shares Down 3%	MT
Sep. 16	Haisco Pharmaceutical Gets Regulatory Approval for New Indication of Anruikefen Injection	MT
Sep. 04	Haisco Pharmaceutical Gets China Clinical Trial Approval for Autoimmune Disease Drug	MT
Sep. 02	Haisco Pharmaceutical Gets Nod From US FDA to Trial Lymphoma Drug	MT
Aug. 25	Haisco Pharmaceutical Group H1 Profit Down 22%, Revenue Up 19%	MT
Aug. 22	Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
Aug. 13	Haisco Pharmaceutical Gets Clinical Trial Approval for Blood Cancer Drug; Shares Jump 6%	MT
Aug. 07	Haisco Pharmaceutical Gets Nod to Trial Autoimmune Disease Drug	MT
Aug. 01	Haisco Pharmaceutical Group Gets US FDA Acceptance for New Drug Application for Anesthetic	MT
Jul. 16	Haisco Pharmaceutical Receives US FDA Approval for Autoimmune Drug Trials	MT
Jul. 07	Haisco Pharmaceutical to Raise 1.37 Billion Yuan via Share Placement; Shares Slump 5%	MT
Jul. 02	Haisco Pharmaceutical Gets Clinical Trial Nod for Muscle Dystrophy Drug	MT
Jun. 24	Haisco Pharmaceutical Group Gets Acceptance Notice for New Indication for HSK47388	MT
Jun. 03	Chinese Drug Regulator Accepts Haisco Pharmaceutical's Application for Autoimmune Drug's Trial	MT
May. 07	Haisco Pharmaceutical Group Co., Ltd. Approves A Share Cash Dividend for the Year 2024, Payable on 15 May 2025	CI
May. 06	Intech Biopharm Ltd. Signs Supplemental Agreement for the SYN010 Product with Haisco Pharmaceutical Group	CI
May. 06	Declaration of Voting Results by Haisco Pharmaceutical Group	CI
Apr. 24	Haisco Pharmaceutical Group Co Receives a Proposal from Wang Junmin	CI
Apr. 24	Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
Apr. 14	Haisco Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2024	CI

Chart Haisco Pharmaceutical Group Co., Ltd.

Duration

Period

Chart Haisco Pharmaceutical Group Co., Ltd.

002653: Dynamic Chart

Haisco Pharmaceutical Group Co.,Ltd., formerly Xizang Haisco Pharmaceutical Group Co., Ltd., is a China-based company principally engaged in the research, development, manufacture and sale of new drugs and high-end medical instrument. The Companyâs main products are categorized into small volume injections, big volume injections, freeze-dried powder injections and others, which include polyene phosphatidylcholine injections, lipid solubility vitamins injection series, doradiazine methanesulfonate injections, nalmefene hydrochloride injections, fluprofen tromethamine tablets and cefoperazone sodium tazobactam sodium for injections, among others. The Company distributes its products in domestic market.

Employees

5,337

Sector

Pharmaceuticals

Calendar

Apr. 23 - Q1 2026 Earnings Release (Projected)

More about the company